HOME

TheInfoList



OR:

Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in
Paris Paris () is the Capital city, capital and List of communes in France with over 20,000 inhabitants, largest city of France. With an estimated population of 2,048,472 residents in January 2025 in an area of more than , Paris is the List of ci ...
, France. The corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers. It changed its name back to Sanofi in May 2011. The company trades as "SAN" on
Euronext Paris Euronext Paris, formerly known as the Paris Bourse (), is a regulated securities trading venue in France. It is Europe's second largest stock exchange by market capitalization, behind the London Stock Exchange, as of December 2023. As of 2022, th ...
and "SNY" on
Nasdaq The Nasdaq Stock Market (; National Association of Securities Dealers Automated Quotations) is an American stock exchange based in New York City. It is the most active stock trading venue in the U.S. by volume, and ranked second on the list ...
in the United States, and is a component of the Euro Stoxx 50
stock market index In finance, a stock index, or stock market index, is an Index (economics), index that measures the performance of a stock market, or of a subset of a stock market. It helps investors compare current stock price levels with past prices to calcul ...
. In 2023, the company’s seat in
Forbes Global 2000 The ''Forbes'' Global 2000 is an annual ranking of the top 2000 public companies in the world, published by: sales, profit, assets and market value. The list has been published annually since 2003. By country Forbes Global 2000 as of 2023: ...
was 89. Sanofi engages in the
research and development Research and development (R&D or R+D), known in some countries as OKB, experiment and design, is the set of innovative activities undertaken by corporations or governments in developing new services or products. R&D constitutes the first stage ...
, manufacturing, and marketing of pharmacological products, principally in the prescription market, but the firm also develops over-the-counter medications. The corporation covers seven major therapeutic areas:
cardiovascular In vertebrates, the circulatory system is a system of organs that includes the heart, blood vessels, and blood which is circulated throughout the body. It includes the cardiovascular system, or vascular system, that consists of the heart a ...
,
central nervous system The central nervous system (CNS) is the part of the nervous system consisting primarily of the brain, spinal cord and retina. The CNS is so named because the brain integrates the received information and coordinates and influences the activity o ...
,
diabetes Diabetes mellitus, commonly known as diabetes, is a group of common endocrine diseases characterized by sustained high blood sugar levels. Diabetes is due to either the pancreas not producing enough of the hormone insulin, or the cells of th ...
,
internal medicine Internal medicine, also known as general medicine in Commonwealth nations, is a medical specialty for medical doctors focused on the prevention, diagnosis, and treatment of diseases in adults. Its namesake stems from "treatment of diseases of ...
,
oncology Oncology is a branch of medicine that deals with the study, treatment, diagnosis, and prevention of cancer. A medical professional who practices oncology is an ''oncologist''. The name's Etymology, etymological origin is the Greek word ὄγ ...
,
thrombosis Thrombosis () is the formation of a Thrombus, blood clot inside a blood vessel, obstructing the flow of blood through the circulatory system. When a blood vessel (a vein or an artery) is injured, the body uses platelets (thrombocytes) and fib ...
, and
vaccine A vaccine is a biological Dosage form, preparation that provides active acquired immunity to a particular infectious disease, infectious or cancer, malignant disease. The safety and effectiveness of vaccines has been widely studied and verifi ...
s. It is the world's largest producer of vaccines through its subsidiary
Sanofi Pasteur Sanofi Pasteur is the vaccines division of the French multinational pharmaceutical company Sanofi. Sanofi Pasteur is the largest company in the world devoted entirely to vaccines. It is one of four global producers of the yellow fever vaccin ...
.


History


Sanofi-Synthélabo

Sanofi was founded on 15 February 1973 as a subsidiary of Elf Aquitaine (a French oil company subsequently acquired by Total), when Elf Aquitaine took control of the Labaz group, a pharmaceutical company formed in 1947 by Sociéte Belge de l'Azote et des Produits Chimiques du Marly; Labaz developed benziodarone in 1957. In 1993, Sanofi made a move into the Eastern Europe market by acquiring a controlling interest in Chinoin, a Hungarian drug company whose 1992, sales totaled about US$104 million.Staff, The Pharma Letter. Sept 20, 199
Sanofi Extends Holding in Chinoin
/ref> In the same year, Sanofi made its first significant venture into the US, and strengthened its presence in Eastern Europe, by first partnering with Sterling Winthrop and then acquiring the prescription pharmaceuticals business in 1994. Sanofi was incorporated under the laws of France in 1994, as a ''société anonyme'', a form of limited liability company.Sanofi-Synthélab
Form 20F for the Fiscal Year ended 31 December 2002
/ref> Synthélabo was founded in 1970, through the merger of two French pharmaceutical laboratories, Laboratoires Dausse (founded in 1834)б and Laboratoires Robert & Carrière (founded in 1899). In 1973, the French cosmetics group L'Oréal acquired the majority of its share capital. In 1991, Synthelabo acquired Laboratories Delalande and Laboratoires Delagrange, and through this deal picked up the product
metoclopramide Metoclopramide is a medication used to treat nausea, vomiting, gastroparesis, and gastroesophageal reflux disease. It is also used to treat migraine headaches. Common side effects include feeling tired, diarrhea, akathisia, and tardive dyski ...
. Sanofi-Synthélabo was formed in 1999 when Sanofi merged with Synthélabo; at the time of the merger, Sanofi was the second largest pharmaceutical group in France in terms of sales and Synthélabo was the third largest. The merged company was based in Paris, France. The merged companies focused on pharmaceuticals, divesting several businesses soon after the merger, including beauty, diagnostics, animal health and nutrition, custom chemicals, and two medical equipment businesses.


Aventis

Aventis was formed in 1999, when the French company Rhône-Poulenc S.A. merged with the German corporation Hoechst Marion Roussel, which itself was formed from the 1995 merger of
Hoechst AG Hoechst AG () was a German chemicals, later life sciences, company that became Aventis Deutschland after its merger with France's Rhône-Poulenc S.A. in 1999. With the new company's 2004 merger with Sanofi-Synthélabo, it became a subsidiar ...
with Cassella, Roussel Uclaf, and Marion Merrell Dow.
Hoechst AG Hoechst AG () was a German chemicals, later life sciences, company that became Aventis Deutschland after its merger with France's Rhône-Poulenc S.A. in 1999. With the new company's 2004 merger with Sanofi-Synthélabo, it became a subsidiar ...
, the majority partner at the time in Hoechst Marion Roussel, was itself a merger of two of the three forcibly separated subsidiaries of
IG Farben I. G. Farbenindustrie AG, commonly known as IG Farben, was a German Chemical industry, chemical and Pharmaceutical industry, pharmaceutical conglomerate (company), conglomerate. It was formed on December 2, 1925 from a merger of six chemical co ...
, exploiter of Auschwitz slave labor and supplier of Zyklon B during
The Holocaust The Holocaust (), known in Hebrew language, Hebrew as the (), was the genocide of History of the Jews in Europe, European Jews during World War II. From 1941 to 1945, Nazi Germany and Collaboration with Nazi Germany and Fascist Italy ...
. The merged company was based in Schiltigheim, near
Strasbourg Strasbourg ( , ; ; ) is the Prefectures in France, prefecture and largest city of the Grand Est Regions of France, region of Geography of France, eastern France, in the historic region of Alsace. It is the prefecture of the Bas-Rhin Departmen ...
, France.Aventi
Form 20-F for the fiscal year ended 31 December 2002
/ref>Arturo Bris and Christos Cabolis
Corporate Governance Convergence Through Cross-Border Mergers The Case of Aventis
Chapter 4 i

Eds Greg N. Gregoriou, Luc Renneboog. Academic Press, 26 July 2007
Lawton Robert Burns
The Business of Healthcare Innovation
Cambridge University Press, 26 July 2012
At the time of the merger, Rhône-Poulenc's business included the pharmaceutical businesses Rorer, Centeon (blood products), and Pasteur Merieux (vaccines), the plant and animal health businesses Rhône-Poulenc Agro, Rhône-Poulenc Animal Nutrition, and
Merial Boehringer Ingelheim Animal Health is a Multinational corporation, multinational animal health company, formed in January 2017 when Merial was acquired by Boehringer Ingelheim and merged with Boehringer Ingelheim's existing animal health assets. ...
, and a 67 percent share in Rhodia, a speciality chemicals company. Hoechst, one of the companies that resulted from the post-WWII split of
IG Farben I. G. Farbenindustrie AG, commonly known as IG Farben, was a German Chemical industry, chemical and Pharmaceutical industry, pharmaceutical conglomerate (company), conglomerate. It was formed on December 2, 1925 from a merger of six chemical co ...
, had seven primary businesses: Hoechst Marion Roussel (pharmaceuticals), AgrEvo (a joint venture with Schering in crop protection agents and pest control products), HR Vet (veterinary products), Dade Behring (diagnostics), Centeon, Celanese (chemicals), and Messer (chemicals). Merieux has been in the business of selling blood products, and in the 1980s, during the AIDS epidemic, Merieux and other companies were involved in scandals related to HIV- contaminated haemophilia blood products that were sold to developing nations. In 2000, Aventis and Millennium Pharmaceuticals, a US biotechnology company formed to discover new drugs based on the then-new science of
genomics Genomics is an interdisciplinary field of molecular biology focusing on the structure, function, evolution, mapping, and editing of genomes. A genome is an organism's complete set of DNA, including all of its genes as well as its hierarchical, ...
, announced that Aventis would make a $250M investment in Millennium and would pay $200M to Millennium in research fees over five years, one of the largest such deals between a big pharmaceutical company and a biotech company at the time. In late 2000, in the midst of the recall of Starlink, its genetically modified maize product, Aventis announced that it had determined to sell off Aventis Cropscience, the seed and pesticide business unit it had created from the agriculture businesses of its predecessors. In October 2001,
Bayer Bayer AG (English: , commonly pronounced ; ) is a German multinational pharmaceutical and biotechnology company and is one of the largest pharmaceutical companies and biomedical companies in the world. Headquartered in Leverkusen, Bayer' ...
and Aventis announced that Bayer would acquire the unit for about $6.6 billion; the unit became Bayer CropScience, making Bayer the world's second-largest agrochemical company behind
Syngenta Syngenta Global AG is a global agricultural technology company headquartered in Basel, Switzerland. It primarily covers crop protection and seeds for farmers. Syngenta is part of the Syngenta Group, entirely owned by Sinochem, a Chinese state ...
. In 2003, Aventis entered into a collaboration with Regeneron Pharmaceuticals, a New York biotechnology company, to develop Regeneron's VEGF-inhibiting drug, aflibercept, which was then in Phase I clinical trials. Aventis invested $45 million in Regeneron and made an upfront payment of $80 million in cash. Regeneron partnered the use of the drug with Bayer Healthcare in the field of proliferative eye diseases, and under the name Eylea it was approved by the US
Food and Drug Administration The United States Food and Drug Administration (FDA or US FDA) is a List of United States federal agencies, federal agency of the United States Department of Health and Human Services, Department of Health and Human Services. The FDA is respo ...
(FDA) in 2011; after several setbacks in clinical trials, Regeneron and Sanofi got the drug approved for metastatic colorectal cancer in combination with other agents, under the brand name Zaltrap in 2012.


Sanofi-Aventis merger

Sanofi-Aventis was formed in 2004, when Sanofi-Synthélabo acquired Aventis. In early 2004, Sanofi-Synthélabo made a
hostile takeover In business, a takeover is the purchase of one company (law), company (the ''target'') by another (the ''acquirer'' or ''bidder''). In the UK, the term refers to the acquisition of a public company whose shares are publicly listed, in contrast t ...
bid for Aventis worth €47.8 billion. Initially, Aventis rejected the bid because it felt that the bid offered inferior value based on the company's share value, and the board of Aventis went so far as to enact poison pill provisions and to invite
Novartis Novartis AG is a Swiss multinational corporation, multinational pharmaceutical company, pharmaceutical corporation based in Basel, Switzerland. Novartis is one of the largest pharmaceutical companies in the world and was the eighth largest by re ...
to enter merger negotiations. The three-month takeover battle concluded when Sanofi-Synthélabo launched a friendly bid of €54.5 billion in place of the previously rejected hostile bid. The French government played a strong role, desiring what it called a "local solution", by putting heavy pressure on Sanofi-Synthélabo to raise its bid for Aventis and for Aventis to accept the offer and by rejecting Aventis's poison pill proposal. One of the largest risks in the deal for both sides was the fate of the patents protecting
Clopidogrel Clopidogrel, sold under the brand name Plavix among others, is an antiplatelet drug, antiplatelet medication used to reduce the risk of Cardiovascular disease, heart disease and stroke in those at high risk. It is also used together with aspi ...
(Plavix), which was one of the top-selling drugs in the world at the time and the major source of Sanofi's revenue.


Post-merger activities

In 2006, Iraqis infected with HIV sued Sanofi and Baxter over HIV- contaminated haemophilia blood products sold by Merieux in the 1980s. In 2006, the US patents on
clopidogrel Clopidogrel, sold under the brand name Plavix among others, is an antiplatelet drug, antiplatelet medication used to reduce the risk of Cardiovascular disease, heart disease and stroke in those at high risk. It is also used together with aspi ...
(Plavix) were challenged when a Canadian generics company, Apotex, filed an Abbreviated New Drug Application under the Hatch-Waxman Act, received FDA approval, and started marketing a generic formulation of clopidogrel. While Sanofi-Aventis and its partner in the drug,
Bristol Myers Squibb The Bristol-Myers Squibb Company, Trade name, doing business as Bristol Myers Squibb (BMS), is an American multinational pharmaceutical company. Headquartered in Princeton, New Jersey, BMS is one of the world's largest pharmaceutical companies ...
(BMS), were able to get an injunction to stop Apotex from selling it, the case became complicated when settlement negotiations fell apart twice – the second time because of an oral agreement made by BMS CEO Peter Dolan that BMS failed to disclose to the
Federal Trade Commission The Federal Trade Commission (FTC) is an independent agency of the United States government whose principal mission is the enforcement of civil (non-criminal) United States antitrust law, antitrust law and the promotion of consumer protection. It ...
during the review of the settlement agreement to ensure that it did not violate
antitrust Competition law is the field of law that promotes or seeks to maintain market competition by regulating anti-competitive conduct by companies. Competition law is implemented through public and private enforcement. It is also known as antitrust l ...
law. When Apotex disclosed the oral agreement to the FTC, the FTC launched an investigation that led to Dolan's dismissal by BMS. Apotex finally lost on the patent litigation issues after its third appeal was decided in favor of BMS/Sanofi in November 2011; Apotex had to pay ~$442 million in damages and ~$108 million in interest for infringing the patent, which it paid in full by February 2012. Apotex also sued BMS and Sanofi for $3.4 billion for allegedly breaching the settlement agreement; Apotex lost a jury trial in March 2013. In 2007, Sanofi-Aventis expanded on Aventis's prior relationship with Regeneron Pharmaceuticals; in the new deal Sanofi-Aventis agreed to pay Regeneron $100 million per year for five years, under which Regeneron would use its
monoclonal antibody A monoclonal antibody (mAb, more rarely called moAb) is an antibody produced from a cell lineage made by cloning a unique white blood cell. All subsequent antibodies derived this way trace back to a unique parent cell. Monoclonal antibodie ...
discovery Discovery may refer to: * Discovery (observation), observing or finding something unknown * Discovery (fiction), a character's learning something unknown * Discovery (law), a process in courts of law relating to evidence Discovery, The Discovery ...
platform to create new biopharmaceuticals, to which Sanofi-Aventis gained the exclusive right to co-develop. In 2009, the companies expanded the deal to $160 million per year and extended it to 2017.Genetic Engineering and Biotechnology News. 11 November 200
Sanofi-Aventis Commits Over $2.8B to Regeneron in mAb Discovery Alliance
/ref> , the collaboration had four antibodies in clinical development and had filed an IND for a fifth. Two were against undisclosed targets, one targeted the interleukin-6
receptor Receptor may refer to: * Sensory receptor, in physiology, any neurite structure that, on receiving environmental stimuli, produces an informative nerve impulse *Receptor (biochemistry), in biochemistry, a protein molecule that receives and respond ...
as a treatment for
rheumatoid arthritis Rheumatoid arthritis (RA) is a long-term autoimmune disorder that primarily affects synovial joint, joints. It typically results in warm, swollen, and painful joints. Pain and stiffness often worsen following rest. Most commonly, the wrist and h ...
, another targeted nerve growth factor for the treatment of pain, and another targeted delta-like ligand 4 as a cancer treatment. Between 2008, when Chris Viehbacher was hired as CEO, and 2010, the company spent more than $17 billion in mergers and acquisitions to strengthen its consumer healthcare and generics platforms, especially in emerging markets, in the face of looming
patent cliff The term patent cliff refers to the phenomenon of patent expiration dates and an abrupt drop in sales that follows for a group of products capturing a high percentage of a market. Usually, these phenomena are noticed when they affect ''blockbuster ...
s and the growth of the consumer healthcare segment. In September, Zentiva was acquired for €1.8 billion, expanding the group's presence in eastern European markets. In 2009, Medley Farma, the third largest pharmaceutical company in Brazil and a leading generics company there, was acquired for about $635 million.Leigh Kamping-Carder for Law360. 20 May 201
Brazil Clears Sanofi's $635M Medley Pharma Buy
/ref> Sanofi outbid
Teva Pharmaceuticals Teva Pharmaceutical Industries Ltd. (also known as Teva Pharmaceuticals) is an Israeli multinational Pharmaceutical industry, pharmaceutical company. Teva specializes primarily in generic drugs, but other business interests include branded-drug ...
. The deal was approved by Brazil's antitrust authorities in May 2010. Later that year, Indian vaccine manufacturer
Shantha Biotechnics Shantha Biotechnics Limited is an Indian biotechnology company headquartered in Hyderabad, India. It is the first Indian company to develop, manufacture and market Recombinant DNA, recombinant human healthcare products in India. The company is a ...
was acquired for $784 million. In October Sanofi-Aventis announced that it would lay off about 1700 US employees (about 25% of its US workforce) because of restructuring triggered by growing generic competition and other factors, and that the company would focus its US operations on diabetes, atrial fibrillation, and oncology. In 2010, US consumer healthcare company Chattem, Inc. was acquired for around $1.9 billion. In the same year, Nepentes Pharma was acquired for $130 million and BMP Sunstone Corporation for $520.6 million.


Name change, acquisitions and investments

The company dropped the -Aventis suffix of its name on May 6, 2011, after receiving approval at its
annual general meeting An annual general meeting (AGM, also known as the annual meeting) is a meeting of the general membership of an organization. These organizations include membership associations and companies with shareholders. These meetings may be required ...
. The reason given by the company for the change was to make its name easier to pronounce in countries such as China. In 2011,
Genzyme Corporation Genzyme (also known as Genzyme Transgenics Corp or GTC Biotherapeutics) was an American biotechnology company based in Cambridge, Massachusetts. From its acquisition in 2011 to 2022 Genzyme operated as a fully owned subsidiary of Sanofi. In 2010, ...
was acquired for around $20.1 billion. This biotechnology company, headquartered in Cambridge, Massachusetts, specializes in the treatment of orphan diseases, renal diseases, endocrinology, oncology, and biosurgery. In January 2012, Sanofi co-invested in the $125 million Series A financing of Warp Drive Bio. Sanofi sought support for its internal cancer research program and also took on an obligation to acquire Warp Drive if certain milestones were met. In January 2014, Genzyme and Alnylam Pharmaceuticals, a US biotechnology company developing RNAi therapeutics, announced that Genyzme would invest $700 million in Alnylam. Under the deal, Genzyme obtained further rights to patisiran, an RNAi treatment for
transthyretin Transthyretin (TTR or TBPA) is a transport protein in the plasma and cerebrospinal fluid that transports the thyroid hormone thyroxine (T4) and retinol to the liver. This is how transthyretin gained its name: ''transports thyroxine and retinol' ...
-mediated amyloidosis – a condition that can result in familial amyloidotic polyneuropathy and familial amyloidotic cardiomyopathy and obtained rights to other compounds in Alnylam's pipeline. In March 2014, Sanofi joined the bidding for Merck & Co.'s over-the-counter health-products unit, the maker of Coppertone sunblock and the antihistamine Claritin; bids were expected to range between $10 billion and $12 billion. In October 2014, Sanofi's directors fired US-resident chief executive Chris Viehbacher, blaming his alleged lack of communication with the board and poor execution of his strategy. Board chairperson Serge Weinberg took over as interim CEO until 2 April 2015 when Bayer Healthcare board chairman Olivier Brandicourt (appointed by Sanofi on 19 February 2015) took over. Before Brandicourt even started his new job, French government ministers Stéphane Le Foll and Ségolène Royal attacked the $4.5 million
golden handshake A golden handshake is a clause in an executive employment contract that provides the executive with a significant severance package in the case that the executive loses their job through firing, restructuring, or even scheduled retirement. Thi ...
he was getting from Sanofi – and his pay of about $4.7 million a year. Furthermore, in 2014, the business took a 66% stake in Globalpharma, a Dubai-based generics manufacturer. In July 2015,
Genzyme Genzyme (also known as Genzyme Transgenics Corp or GTC Biotherapeutics) was an American biotechnology company based in Cambridge, Massachusetts. From its acquisition in 2011 to 2022 Genzyme operated as a fully owned subsidiary of Sanofi. In 2010, ...
announced that it would acquire the cancer drug Caprelsa ( vandetanib) from
AstraZeneca AstraZeneca plc () (AZ) is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, UK. It has a portfolio of products for major diseases in areas includi ...
for up to $300 million. In the same month, the company announced a new global collaboration with Regeneron Pharmaceuticals to discover, develop, and commercialize new immuno-oncology drugs, which could generate more than $2 billion for Regeneron, with $640 million upfront, $750 million for proof of concept data, and $650 million from the development of REGN2810. In June 2016, the company announced that it had struck an asset-swap deal with
Boehringer Ingelheim C.H. Boehringer Sohn AG & Co. is the parent company of the Boehringer Ingelheim group, which was founded in 1885 by Albert Boehringer (1861–1939) in Ingelheim am Rhein, Germany. As of 2018, Boehringer Ingelheim is one of the world's List of la ...
. Sanofi would sell its
Merial Boehringer Ingelheim Animal Health is a Multinational corporation, multinational animal health company, formed in January 2017 when Merial was acquired by Boehringer Ingelheim and merged with Boehringer Ingelheim's existing animal health assets. ...
animal health division (valuing it at €11.4 billion), while acquiring Boehringer's consumer health division (valuing it at €6.7 billion) and €4.7 billion in cash. The deal meant that Sanofi was now one of the global consumer healthcare leaders by market share. In July 2017, the company announced its intention to acquire Protein Sciences, a privately held Connecticut-based vaccines biotechnology company, for $650 million and with up to $100 million in milestone achievements. In January 2018, Sanofi announced that it would acquire Bioverativ for $11.6 billion and days later announced that it would acquire Ablynx for €3.9 billion ($4.8 billion). In December 2019, the company announced that it would acquire Synthorx for $2.5 billion ($68 per share), adding the lead product candidate THOR-707 (SAR444245), a form of interleukin-2 (IL-2) being developed for use against multiple solid tumors. In October 2022, Sanofi announced that it had stopped Phase 2 studies of THOR-707 (SAR444245) because the drug's efficacy “was lower than projected”. Sanofi would take a roughly $1.6 billion impairment charge because of delays to the program. In May 2020, Regeneron announced that it would repurchase around $5 billion of its shares held directly by Sanofi. Before the transaction, Sanofi had held 23.2 million Regeneron shares. In June, the company announced that it had agreed a potential $2 billion deal with Translate Bio, expanding an already existing collaboration for COVID-19 treatments. The company agreed to produce 60 million doses of a coronavirus vaccine for the United Kingdom government in July 2020. It used recombinant protein-based technology for Sanofi's flu vaccine along with GSK's pandemic technology and was seeking regulatory approval by the first half of 2021. Sanofi also agreed to a $2.1 billion deal with the United States for 100 million doses. In August, Sanofi announced that it would acquire Principia Biopharma for $3.7 billion, acquiring its BTK inhibitor program. The acquisition was completed in September 2020. In November, Sanofi announced that it would acquire Kiadis Pharma for €308 million (around $359 million, or €5.45 per share), expanding its immuno-oncology pipeline with the acquisition of Kiadis's three clinical compounds: K-NK002 in Phase II trials for
hematopoietic stem cell Hematopoietic stem cells (HSCs) are the stem cells that give rise to other blood cells. This process is called haematopoiesis. In vertebrates, the first definitive HSCs arise from the ventral endothelial wall of the embryonic aorta within the ...
transplants in blood cancer, K-NK003 for relapsed or refractory
acute myeloid leukemia Acute myeloid leukemia (AML) is a cancer of the myeloid line of blood cells, characterized by the rapid growth of abnormal cells that build up in the bone marrow and blood and interfere with haematopoiesis, normal blood cell production. Sympt ...
, and K-NK-ID101 for
COVID-19 Coronavirus disease 2019 (COVID-19) is a contagious disease caused by the coronavirus SARS-CoV-2. In January 2020, the disease spread worldwide, resulting in the COVID-19 pandemic. The symptoms of COVID‑19 can vary but often include fever ...
. In January 2021, Sanofi announced that it would buy the British biotech Kymab Ltd and its potential first-in-class drug candidate – KY1005 –- for $1.45 billion. In April, the business announced that it would acquire Tidal Therapeutics for up to $470m. in August the company announced that it would acquire Translate Bio and its mRNA vaccine technology for $3.2 billion. On 8 September 2021, Sanofi announced that it would acquire US biotech company Kadmon Corporation for $1.9 billion On 18 November 2021, it was reported that Sanofi would be investing $180 million in French startup Owkin, whose predictive algorithms aim to improve the research and development of new cures against cancer. In December, the company announced that it would acquire Origimm Biotechnology GmbH and its acne vaccine candidate (ORI-001), as well as Amunix Pharmaceuticals, for an initial $1 billion plus potentially $200 million in additional milestones. In April 2022, Sanofi broke ground on its biggest industrial investment, a $638m vaccine and enzymes production facility in Tuas,
Singapore Singapore, officially the Republic of Singapore, is an island country and city-state in Southeast Asia. The country's territory comprises one main island, 63 satellite islands and islets, and one outlying islet. It is about one degree ...
, targeted for completion in 2025. In March 2023, the company announced it would acquire Provention Bio and its type 1 diabetes therapy pipeline. In the fall of 2023, Sanofi announced plans to separate the OTC and focus on its key prescription production, increasing investment and reducing costs. The most likely way to separate a non-prescription division (about 11,000 employees, 2023 revenue — over $4 billion) is to create a public company headquartered in France. The division is planned for the fourth quarter of 2024. In December 2023, the company has signed a 140 million dollars partnership with Aqemia, a company that solves a mathematical equation that eliminates the need for heavy computing facilities with large computing power. In January 2024, Sanofi announced that it had agreed to buy a U.S. biotech firm Inhibrx for up to $2.2 billion, with a focus on obtaining Inhibrx's INBRX-101, an experimental treatment for
Alpha-1 Antitrypsin Deficiency Alpha-1 antitrypsin deficiency (A1AD or AATD) is a genetic disorder that may result in lung disease or liver disease. Onset of lung problems is typically between 20 and 50 years of age. This may result in shortness of breath, wheezing, or an inc ...
(AATD), an inherited rare disease that causes progressive deterioration of the lung tissue. The post-acquisition company now employs more than 90,000 employees in 90 countries. In October 2024, Sanofi and CD&R entered exclusive negotiations to transfer a 50% controlling stake in Opella with Sanofi to remain a significant shareholder. In May 2025, Sanofi announced the buyout of Vigil Neuroscience for $470 million.


Company financials

Note. In 2001–2004: Sanofi-Synthélabo; in 2004–2011: Sanofi-Aventis.


Acquisition history

*Sanofi **Sanofi–Aventis *** Aventis (Merged 2004) **** Rhône-Poulenc (Merged 1999) ***** A. Nattermann (Acq 1986) ***** William H. Rorer, Inc. (Merged 1990) *****Centeon *****Pasteur Merieux *****Rhône-Poulenc Agro *****Rhône-Poulenc Animal Nutrition *****Merial (Sold to
Boehringer Ingelheim C.H. Boehringer Sohn AG & Co. is the parent company of the Boehringer Ingelheim group, which was founded in 1885 by Albert Boehringer (1861–1939) in Ingelheim am Rhein, Germany. As of 2018, Boehringer Ingelheim is one of the world's List of la ...
2016)
***** Rhodia **** Hoechst Marion Roussel (Merged 1999) ***** AgrEvo *****HR Vet ***** Dade Behring *****Centeon ***** Celanese *****Messer ***** Roussel Uclaf (Acq 1997) *** Sanofi-Synthélabo (Merged 2004) ****Sanofi (Est 1973 as subsidiary of Elf Aquitaine) *****Midy ***** Sterling Winthrop (Acq 1994) **** Synthélabo *****Laboratoires Dausse (Founded 1834, merged 1970) *****Robert & Carrière (Founded 1899, merged 1970) *** Zentiva (Acq 2008) ****Leciva Slovakofarma (Acq 2003) ****Sicomed SA Bucharest (Acq 2005) ***Medley Farma (Acq 2009) ***Shantha Biotechnics (Acq 2009) ***Chattem (Acq 2010) ***Nepentes Pharma (Acq 2010) ***BMP Sunstone Corporation (Acq 2010) **
Genzyme Corporation Genzyme (also known as Genzyme Transgenics Corp or GTC Biotherapeutics) was an American biotechnology company based in Cambridge, Massachusetts. From its acquisition in 2011 to 2022 Genzyme operated as a fully owned subsidiary of Sanofi. In 2010, ...
(Acq 2011) ***Whatman Biochemicals Ltd (Acq 1981) ***Koch-Light Laboratories (Acq 1982) ***Integrated Genetics (Acq 1989, spun off 1991) ***Genecore International (Diagnostic enzyme div, acq 1991) ***Medix Biotech, Inc. (Acq 1992) ***Enzymatix Ltd (Acq 1992) ***Vivigen (Acq 1992) ***Virotech (Acq 1993) ***Omni Res srl (Acq 1993) ***Sygena Ltd (Acq 1994) ***BioSurface Technology Inc. (Acq 1994) ***TSI Inc. (Acq 1994) ***PharmaGenics, Inc. (Acq 1997) ***Biomatrix (Acq 2000) ***SangStat Medical Corp. (Acq 2003) ***Ilex Oncology Inc. (Acq 2004) ***Bone Care International Inc. (Acq 2005) ***AnorMED Inc. (Acq 2006) ***Bioenvision (Acq 2007) **Protein Sciences (Acq 2017) ** Bioverativ (Acq 2018) ***True North Therapeutics (Acq 2017) ** Ablynx (Acq 2018) **Synthorx (Acq 2019) **Principia Biopharma (Acq 2020) **Kiadis Pharma (Acq 2020) **Kymab Ltd (Acq 2021) **Tidal Therapeutics (Acq 2021) **Translate Bio (Acq 2021) ** Kadmon Corporation (Acq 2021) **Origimm Biotechnology GmbH (Acq 2021) **Amunix Pharmaceuticals (Acq 2021) **Provention Bio (Acq 2023) **Inhibrx (Acq 2024) **Vigil Neuroscience (Acq 2025)


Products

The following products are listed on the Sanofi Genzyme website.
Generic drug A generic drug is a pharmaceutical drug that contains the same chemical substance as a drug that was originally protected by chemical patents. Generic drugs are allowed for sale after the patents on the original drugs expire. Because the active ch ...
names are given in parentheses following the brand name. –
Autoimmune In immunology, autoimmunity is the system of immune responses of an organism against its own healthy cells, tissues and other normal body constituents. Any disease resulting from this type of immune response is termed an " autoimmune disease" ...
* Aubagio ( Teriflunomide), small molecule for
multiple sclerosis Multiple sclerosis (MS) is an autoimmune disease resulting in damage to myelinthe insulating covers of nerve cellsin the brain and spinal cord. As a demyelinating disease, MS disrupts the nervous system's ability to Action potential, transmit ...
. Approved by the FDA in September 2012. * Auvi-Q ( Epinephrine autoinjector), licensed from Intelliject and approved by the FDA in 2012, for emergency treatment of life-threatening
allergic reactions Allergies, also known as allergic diseases, are various conditions caused by hypersensitivity of the immune system to typically harmless substances in the environment. These diseases include hay fever, food allergies, atopic dermatitis, alle ...
. Product recall and effects: The epinephrine (adrenaline) auto-injection devices made by Sanofi SA currently on the market in the US and Canada were voluntarily recalled on 28 October 2015. The reason given by Sanofi was that the products had been found to potentially have inaccurate dosage delivery systems, which might include failure to deliver the drugs. Sanofi US also added the following warning: If a patient experiencing a serious allergic reaction (i.e., anaphylaxis) did not receive the intended dose, there could be significant health consequences, including death, because anaphylaxis is a potentially life‑threatening condition. In its news release on 28 October 2015, Sanofi Canada stated that it was "actively working with suppliers of alternative epinephrine auto-injectors to have a full stock available in Canada as soon as possible. Canadian customers were asked to immediately return the Allerject product to their local pharmacy to obtain an alternate epinephrine auto-injector." The US
Food and Drug Administration The United States Food and Drug Administration (FDA or US FDA) is a List of United States federal agencies, federal agency of the United States Department of Health and Human Services, Department of Health and Human Services. The FDA is respo ...
(FDA) also filed a news release, confirming that the recall involved all Auvi-Q currently on the market in the United States. The FDA release went on to provide information for consumers re: exchanging the device for another brand of product, also provided on the Auvi-Q web site. Sanofi US would provide reimbursement for out of pocket costs incurred for the purchase of new, alternate epinephrine auto-injectors with proof of purchase. The alternate products expected to most commonly replace the recalled Sanofi devices were the EpiPens made by Mylan in the US and by Pfizer—under license from Mylan—in Canada. Mylan already had an 85% market share of the auto-injectors in the USA in the first half of 2015. Maylan was expected to benefit from the recall by its competitor Sanofi, according to a report published in the Fierce Pharma newsletter of 2 November 2015. As Bernstein analyst Ronny Gal wrote in a note to clients,"....it is very hard to see Auvi-Q returning to the market, as it will need to be redesigned and face uphill battle to recapture patient trust after the recall." Gal also believed that the company would eventually have 95% of the epinephrine auto-injector market, according to another Fierce Pharma report on 3 November 2015. –
Cardiovascular In vertebrates, the circulatory system is a system of organs that includes the heart, blood vessels, and blood which is circulated throughout the body. It includes the cardiovascular system, or vascular system, that consists of the heart a ...
* Adenoscan (
Adenosine Adenosine (symbol A) is an organic compound that occurs widely in nature in the form of diverse derivatives. The molecule consists of an adenine attached to a ribose via a β-N9- glycosidic bond. Adenosine is one of the four nucleoside build ...
), for arrhythmias, marketed by Astellas. * Altace ( Ramipril), for
hypertension Hypertension, also known as high blood pressure, is a Chronic condition, long-term Disease, medical condition in which the blood pressure in the artery, arteries is persistently elevated. High blood pressure usually does not cause symptoms i ...
, marketed by Pfizer. * Arixtra ( Fondaparinux), for thrombosis, marketed by GlaxoSmithKline and now owned by Mylan. * Avalide ( Irbesartan), for
hypertension Hypertension, also known as high blood pressure, is a Chronic condition, long-term Disease, medical condition in which the blood pressure in the artery, arteries is persistently elevated. High blood pressure usually does not cause symptoms i ...
, marketed by Bristol-Myers Squibb. * Avapro ( Irbesartan), for
hypertension Hypertension, also known as high blood pressure, is a Chronic condition, long-term Disease, medical condition in which the blood pressure in the artery, arteries is persistently elevated. High blood pressure usually does not cause symptoms i ...
, marketed by Bristol-Myers Squibb. * Cardizem (
Diltiazem Diltiazem, sold under the brand name Cardizem among others, is a nondihydropyridine calcium channel blocker medication used to treat high blood pressure, angina, and certain heart arrhythmias. It may also be used in hyperthyroidism if beta b ...
), for
hypertension Hypertension, also known as high blood pressure, is a Chronic condition, long-term Disease, medical condition in which the blood pressure in the artery, arteries is persistently elevated. High blood pressure usually does not cause symptoms i ...
, Now owned by Bausch Health. * Cholestagel ( Colesevelam), for low-calorie diet and exercise. * Cordarone (
Amiodarone Amiodarone is an antiarrhythmic medication used to treat and prevent a number of types of cardiac dysrhythmias. This includes ventricular tachycardia, ventricular fibrillation, and wide complex tachycardia, atrial fibrillation, and paroxys ...
), for heart rhythm problems. * Iprivask ( Desirudin), for atherothrombosis, Now owned by Bausch Health. * Kynamro ( Mipomersen), an antisense drug invented by Isis Pharmaceuticals and acquired by Genzyme in 2008, (pre-Sanofi) and approved by the FDA in 2013, for the orphan disease homozygous familial hypercholesterolemia. * Lasix ( Furosemide), for edema. * Lovenox ( Enoxaparin), for thrombosis, (its biggest seller in 2008). * Multaq ( Dronedarone), for cardiac arrhythmias. * Nitrolingual (
Nitroglycerin Nitroglycerin (NG) (alternative spelling nitroglycerine), also known as trinitroglycerol (TNG), nitro, glyceryl trinitrate (GTN), or 1,2,3-trinitroxypropane, is a dense, colorless or pale yellow, oily, explosive liquid most commonly produced by ...
), for chest pain and angina, marketed by G. Pohl-Boskamp GmbH & Co. * Plavix (
Clopidogrel Clopidogrel, sold under the brand name Plavix among others, is an antiplatelet drug, antiplatelet medication used to reduce the risk of Cardiovascular disease, heart disease and stroke in those at high risk. It is also used together with aspi ...
), for atherothrombosis, marketed by Bristol-Myers Squibb. * Praluent ( Alirocumab), for heterozygous familial hypercholesterolemia and clinical atherosclerotic cardiovascular disease, marketed by Regeneron. * Ranexa ( Ranolazine), for stable angina, marketed by Gilead Sciences. –
Dermatology Dermatology is the branch of medicine dealing with the Human skin, skin.''Random House Webster's Unabridged Dictionary.'' Random House, Inc. 2001. Page 537. . It is a speciality with both medical and surgical aspects. A List of dermatologists, ...
* Dupixent ( Dupilumab), for eczema, marketed by Regeneron. * Dynabac ( Dirithromycin), for acute bacteria exacerbations. * Sklice ( Ivermectin), for head lice, now owned by Arbor Pharmaceuticals. –
Diabetes Diabetes mellitus, commonly known as diabetes, is a group of common endocrine diseases characterized by sustained high blood sugar levels. Diabetes is due to either the pancreas not producing enough of the hormone insulin, or the cells of th ...
* Adlyxin ( Lixisenatide), for type 2 diabetes mellitus. * Admelog (insulin lispro), for type 1 and type 2 diabetes mellitus. * Afrezza ( Inhalable insulin), for type 1 and type 2 diabetes mellitus. * Amaryl ( Glimepiride), for type 2 diabetes mellitus. * Apidra (insulin glulisine), for type 1 and type 2 diabetes mellitus. * Diabeta ( Glyburide), for type 2 diabetes mellitus. * Glucophage ( Metformin), for type 2 diabetes mellitus, marketed by EMD Serono. * Insuman ( Human insulin), for type 1 and type 2 diabetes mellitus. * Lantus (insulin glargine), for type 1 and type 2 diabetes mellitus. * Soliqua (insulin glargine/lixisenatide), for type 2 diabetes mellitus. * Toujeo (insulin glargine), for type 1 and type 2
diabetes mellitus Diabetes mellitus, commonly known as diabetes, is a group of common endocrine diseases characterized by sustained hyperglycemia, high blood sugar levels. Diabetes is due to either the pancreas not producing enough of the hormone insulin, or th ...
. –
Endocrinology Endocrinology (from ''endocrine system, endocrine'' + ''wikt:-logy#Suffix, -ology'') is a branch of biology and medicine dealing with the endocrine system, its diseases, and its specific secretions known as hormones. It is also concerned with the ...
* Adlyxin ( Lixisenatide), for type 2 diabetes mellitus. * Admelog (insulin lispro), for type 1 and type 2 diabetes mellitus. * Afrezza ( Inhalable insulin), for type 1 and type 2 diabetes mellitus. * Amaryl ( Glimepiride), for type 2 diabetes mellitus. * Apidra (insulin glulisine), for type 1 and type 2 diabetes mellitus. * Cholestagel ( Colesevelam), for low-calorie diet and exercise. * Diabeta ( Glyburide), for type 2 diabetes mellitus. * Glucophage ( Metformin), for type 2 diabetes mellitus, marketed by EMD Serono. * Hectorol ( Doxercalciferol), for parathyroid hormone. * Insuman ( Human insulin), for type 1 and type 2 diabetes mellitus. * Lantus (insulin glargine), for type 1 and type 2 diabetes mellitus. * Skelid ( Tiludronic acid), for
Paget's disease of bone Paget's disease of bone (commonly known as Paget's disease or, historically, osteitis deformans) is a condition involving Bone remodeling, cellular remodeling and deformity of one or more bones. The affected bones show signs of dysregulated bone ...
. * Soliqua (insulin glargine/lixisenatide), for type 2 diabetes mellitus. * Toujeo (insulin glargine), for type 1 and type 2
diabetes mellitus Diabetes mellitus, commonly known as diabetes, is a group of common endocrine diseases characterized by sustained hyperglycemia, high blood sugar levels. Diabetes is due to either the pancreas not producing enough of the hormone insulin, or th ...
. –
Gastroenterology Gastroenterology (from the Greek gastḗr- "belly", -énteron "intestine", and -logía "study of") is the branch of medicine focused on the digestive system and its disorders. The digestive system consists of the gastrointestinal tract, sometime ...
* Dupixent ( Dupilumab), for eosinophilic esophagitis, marketed by Regeneron. * Lanzor ( Lansoprazole), for acid reflux disease. * Seprafilm ( Adhesion barrier), for internal adhesions. * Zaltrap ( Aflibercept), recombinant fusion protein, approved in metastatic colorectal cancer in combination with other agents in 2012, marketed by Regeneron.
Hematology Hematology (American and British English spelling differences#ae and oe, spelled haematology in British English) is the branch of medicine concerned with the study of the cause, prognosis, treatment, and prevention of diseases related to bloo ...
* Alprolix (
Factor IX Factor IX (), also known as Christmas factor, is one of the serine proteases involved in coagulation; it belongs to peptidase family S1. Deficiency of this protein causes haemophilia B. It was discovered in 1952 after a young boy named Stephen ...
), for hemophilia B. * Arixtra ( Fondaparinux), for thrombosis, marketed by GlaxoSmithKline and now owned by Mylan. * Cablivi ( Caplacizumab), for thrombosis. * Campath ( Alemtuzumab), for
multiple sclerosis Multiple sclerosis (MS) is an autoimmune disease resulting in damage to myelinthe insulating covers of nerve cellsin the brain and spinal cord. As a demyelinating disease, MS disrupts the nervous system's ability to Action potential, transmit ...
. *
Clolar Clofarabine is a purine nucleoside antimetabolite marketed in the United States and Canada as Clolar. In Europe and Australia/New Zealand the product is marketed under the name Evoltra. It is FDA-approved for treating relapsed or refractory ac ...
(
Clofarabine Clofarabine is a purine nucleoside antimetabolite marketed in the United States and Canada as Clolar. In Europe and Australia/New Zealand the product is marketed under the name Evoltra. It is FDA-approved for treating relapsed or refractory a ...
), for leukemia. * Eloctate (
Factor VIII Coagulation factor VIII (Factor VIII, FVIII, also known as anti-hemophilic factor (AHF)) is an essential blood clotting protein. In humans, it is encoded by ''F8'' gene. Defects in this gene result in hemophilia A, an X-linked bleeding disorder ...
), for hemophilia A. * Ferrlecit ( Sodium ferric gluconate complex), for iron deficiency anemia. * Fludara ( Fludarabine), for leukemia. * Mozobil ( Plerixafor), for macrocycle, approved by the FDA for peripheral blood stem cell mobilizer for non-Hodgkin's lymphoma and multiple myeloma in December 2008. * Oforta ( Fludarabine), for leukemia. * Thymoglobulin, for hemophilia A. * Zemaira (
Alpha-1 antitrypsin Alpha-1 antitrypsin or α1-antitrypsin (A1AT, α1AT, A1A, or AAT) is a protein belonging to the serpin superfamily. It is encoded in humans by the ''SERPINA1'' gene. A protease inhibitor, it is also known as alpha1–proteinase inhibitor (A1P ...
), for chronic augmentation, Now owned by CSL Behring. – Infectious diseases * Antibiotics: * Amoklavin ( Amoxicillin/clavulanic acid) * Claforan (
Cefotaxime Cefotaxime is an antibiotic used to treat several bacterial infections in humans, other animals, and plant tissue culture. Specifically in humans it is used to treat joint infections, pelvic inflammatory disease, meningitis, pneumonia, urin ...
) * Priftin ( Rifapentine) * Suprax ( Cefixime) * Tavanic (
Levofloxacin Levofloxacin, sold under the brand name Levaquin among others, is a broad-spectrum antibiotic of the fluoroquinolone drug class. It is the left-handed isomer of the medication ofloxacin. It is used to treat a number of bacterial infections ...
) * Vaccines: **Bacterial diseases: * ActHIB ( Hib vaccine) * Adacel (
DPT vaccine The DPT vaccine or DTP vaccine is a class of combination vaccines to protect against three infectious diseases in humans: diphtheria, pertussis (whooping cough), and tetanus (lockjaw). The vaccine components include diphtheria and tetanus t ...
) * Daptacel (
DPT vaccine The DPT vaccine or DTP vaccine is a class of combination vaccines to protect against three infectious diseases in humans: diphtheria, pertussis (whooping cough), and tetanus (lockjaw). The vaccine components include diphtheria and tetanus t ...
) * Dengvaxia (Dengue vaccine) * Menactra (Meningococcal vaccine, Meningococcal infections) * Mycobax (Tuberculosis vaccine) * Pentacel (DTaP-IPV/Hib vaccine) * Pneumo 23 (Pneumococcal vaccine, Pneumococcal infections) * Quadracel (DTaP-IPV/Hib vaccine) * Shanchol (Cholera vaccine) * Synercid (Quinupristin/dalfopristin), marketed by Pfizer. * Tenivac (Tetanus vaccine) * Tripedia (
DPT vaccine The DPT vaccine or DTP vaccine is a class of combination vaccines to protect against three infectious diseases in humans: diphtheria, pertussis (whooping cough), and tetanus (lockjaw). The vaccine components include diphtheria and tetanus t ...
), discontinued in 2012. * Tubersol (Tuberculosis vaccine) * Typhim Vi (Typhoid fever) * Vaccin Tetanique Pasteur (Tetanus vaccine) **Viral diseases: * ACAM 2000 (Smallpox vaccine), eradicated in 1980 (vaccine produced as a measure in response to the threat of bioterrorism). * Avaxim (Hepatitis A vaccine) * Flublok (Influenza vaccine) * Fluzone (Influenza vaccine) * Hbvaxpro (Hepatitis B vaccine) * Imovax Polio (Polio vaccine) * Imovax Rabies (Rabies vaccine) * Ipol (Polio vaccine) * Ixiaro (Japanese encephalitis) * M-M-RVaxPro (MMR vaccine) * Rouvax (Measles vaccine) * Rudivax (Rubella vaccine) * Stamaril (Yellow fever vaccine) * Vaxigrip (Influenza vaccine) * YF-VAX (Yellow fever vaccine) – Metabolic * Actonel (Risedronic acid), for osteoporosis and Paget's disease of bone, Paget's disease, now owned by Allergan. * Renagel (Sevelamer) hydrochloride, for Chronic kidney disease, end stage renal disease. * Renvela (Sevelamer) hydrochloride, for Chronic kidney disease, end stage renal disease. – Neurology * Ambien (Zolpidem), for insomnia. * Ambien CR (Zolpidem), for insomnia. * Aubagio ( Teriflunomide), for
multiple sclerosis Multiple sclerosis (MS) is an autoimmune disease resulting in damage to myelinthe insulating covers of nerve cellsin the brain and spinal cord. As a demyelinating disease, MS disrupts the nervous system's ability to Action potential, transmit ...
. * Depakine (Valproic acid), for epilepsy, now owned by AbbVie. * Depakote (Valproate semisodium), for epilepsy, now owned by AbbVie. * Hyalgan (Sodium hyaluronate), for blood tests. * Lemtrada ( Alemtuzumab), for
multiple sclerosis Multiple sclerosis (MS) is an autoimmune disease resulting in damage to myelinthe insulating covers of nerve cellsin the brain and spinal cord. As a demyelinating disease, MS disrupts the nervous system's ability to Action potential, transmit ...
. * Pediapred (Prednisolone), for
multiple sclerosis Multiple sclerosis (MS) is an autoimmune disease resulting in damage to myelinthe insulating covers of nerve cellsin the brain and spinal cord. As a demyelinating disease, MS disrupts the nervous system's ability to Action potential, transmit ...
. * Rilutek (Riluzole), for ALS. * Sabril (Vigabatrin), for epilepsy, marketed by Lundbeck. – Oncology * Anzemet (Dolasetron), for nausea and vomiting. * Campath ( Alemtuzumab), for
multiple sclerosis Multiple sclerosis (MS) is an autoimmune disease resulting in damage to myelinthe insulating covers of nerve cellsin the brain and spinal cord. As a demyelinating disease, MS disrupts the nervous system's ability to Action potential, transmit ...
. * Caprelsa (Vandetanib), for breast, colorectal cancer and female infertility. *
Clolar Clofarabine is a purine nucleoside antimetabolite marketed in the United States and Canada as Clolar. In Europe and Australia/New Zealand the product is marketed under the name Evoltra. It is FDA-approved for treating relapsed or refractory ac ...
(
Clofarabine Clofarabine is a purine nucleoside antimetabolite marketed in the United States and Canada as Clolar. In Europe and Australia/New Zealand the product is marketed under the name Evoltra. It is FDA-approved for treating relapsed or refractory a ...
), for leukemia. * Clomid (Clomifene), for female infertility. * Dupixent ( Dupilumab), for eczema, marketed by Regeneron. * Eligard (Leuprorelin), for prostate cancer, marketed by Astellas. * Elitek (Rasburicase), for the treatment to help stop uric acid. * Eloxatin (Oxaliplatin), for colorectal cancer. * Fludara ( Fludarabine), for leukemia. * Gliadel Wafer (Carmustine), for cancer, now owned by Arbor Pharmaceuticals. * Jevtana (Cabazitaxel), for prostate cancer. * Kevzara (Sarilumab), for blood tests, lung cancer, lung and prostate cancer, marketed by Regeneron. * Libtayo (Cemiplimab), for squamous cell skin cancer, marketed by Regeneron. * Mozobil ( Plerixafor), macrocycle, approved by the FDA for peripheral blood stem cell mobilizer for non-Hodgkin's lymphoma and multiple myeloma in December 2008. * Oforta ( Fludarabine), for leukemia. * Taxotere (Docetaxel), for breast cancer, breast, lung cancer, lung and prostate cancer. * Uroxatral (Alfuzosin), for benign prostatic hyperplasia. * Zaltrap ( Aflibercept), recombinant fusion protein, approved in metastatic colorectal cancer in combination with other agents in 2012, marketed by Regeneron. – Other * Aldurazyme (Laronidase), for hurler syndrome. * Aplenzin (Bupropion), for depression and quit smoking. * Captique (Dermal filler), for facial wrinkles. * Carticel (Knee cartilage replacement therapy), for knee pain. * Cerdelga (Eliglustat), for type 1 gaucher disease. * Ceredase (Alglucerase), for Gaucher's disease. * Cerezyme (Imiglucerase), for Gaucher's disease. * Elaprase (Idursulfase), marketed by Shire. * Epicel (cultured epidermal autografts), for thickness burns. * Fabrazyme (Agalsidase), for Fabry disease. * Flagyl (Metronidazole), for vaginal infections, marketed by Pfizer. * Hylaform Plus (Injectable filler), for facial wrinkles. * Lumizyme (Alglucosidase alfa), for Pompe disease. * Myozyme (Alglucosidase alfa), for Pompe disease. * Sculptra (Polylactic acid), for facial fat loss. * Thyrogen (Thyroid-stimulating hormone), for thyroid cancer. – Over the counter * Allegra (Fexofenadine), for allergic rhinitis. * Buscopan (Hyoscine butylbromide), for abdominal pain. * Maalox (Calcium carbonate#Health and dietary applications, Calcium carbonate), an antacid. * Nasacort (Triamcinolone), for allergic rhinitis. * Novaldol (Paracetamol), for pain and fever. * Unisom (Doxylamine), for night-time allergy and cold relief. * Xyzal (Levocetirizine), for allergic rhinitis, marketed by UCB. * Telfast for Seasonal Allergy Relief * Enterogermina Medicine for Diarrhea – Pain * Bi-profined (Ketoprofen), for pain. * Solpadol (Codeine), for chronic pain. – Respiratory and inflammatory diseases * Atrovent (Ipratropium bromide), for asthma, marketed by Boehringer Ingelheim. * Azmacort (Triamcinolone), for asthma. * Dupixent ( Dupilumab), for eosinophilic asthma and chronic rhinosinusitis with nasal polyposis, marketed by Regeneron. * Dynabac ( Dirithromycin), for acute bacterial exacerbations. * Ketek (Telithromycin), for community acquired pneumonia. * Priftin ( Rifapentine), for tuberculosis. * Rifadin (Rifampin), for tuberculosis. * Rifamate (Isoniazid/rifampicin), for tuberculosis. * Rifater (Rifampicin/isoniazid/pyrazinamide), for tuberculosis. * Tilade (Nedocromil), for asthma. * Zagam (Sparfloxacin), for chronic bronchitis. * Zemaira (
Alpha-1 antitrypsin Alpha-1 antitrypsin or α1-antitrypsin (A1AT, α1AT, A1A, or AAT) is a protein belonging to the serpin superfamily. It is encoded in humans by the ''SERPINA1'' gene. A protease inhibitor, it is also known as alpha1–proteinase inhibitor (A1P ...
), for chronic augmentation, now owned by CSL Behring. * Mucosolvan Medicine for Cough – Rheumatology * Arava (Leflunomide), for rheumatoid arthritis, rheumatoid and psoriatic arthritis. * Kevzara (Sarilumab), for blood tests, lung cancer, lung and prostate cancer, marketed by Regeneron. * Primaquine (Primaquine), for malaria. * Synvisc (Hyaluronic acid), for knee pain. – Urology * Ditropan XL (Oxybutynin chloride), for bladder relief, marketed by Janssen. * Eligard (Leuprorelin), for prostate cancer, marketed by Astellas. * Flomax (Tamsulosin), for bladder relief, marketed by Astellas. The company also produces a broad range of over-the-counter products, among them Fexofenadine, Allegra, IcyHot for muscle pain, Gold Bond medicated powder, Gold Bond for skin irritation, and Selsun Blue dandruff shampoo. These brands were acquired in 2010, when Sanofi-Aventis purchased Chattem.


Pipeline

, Sanofi was in a race with Amgen and Pfizer to win approval for a PCSK9 inhibitor, drug that inhibits PCSK9, a protein that slows the clearance of low-density lipoprotein (LDL) cholesterol – the form of cholesterol that leads to heart attacks. Sanofi's drug, a
monoclonal antibody A monoclonal antibody (mAb, more rarely called moAb) is an antibody produced from a cell lineage made by cloning a unique white blood cell. All subsequent antibodies derived this way trace back to a unique parent cell. Monoclonal antibodie ...
, was discovered by Regeneron Pharmaceuticals and is called alirocumab. An FDA warning in March 2014, about possible cognitive adverse effects of PCSK9 inhibition threw the competition into disarray, as the FDA asked companies to include neurocognitive testing into their Phase III clinical trials. In 2013, Sanofi announced that another candidate from its collaboration with Regeneron, a monoclonal antibody against the interleukin 6 receptor, sarilumab, had better efficacy than placebo in its first Phase III trial in rheumatoid arthritis.


Management

* Serge Weinberg, chairman of the board, chairman * Paul Hudson (businessman), Paul Hudson, CEO, chief executive officer * Jean-François Dehecq was the general manager of Sanofi from its creation in 1973 until 2007. * François-Xavier Roger, Chief financial officer, CFO


Stockholders

As of 31 December 2013: * Breakdown of share ownership: 8.93% by L'Oréal, 0.27% treasury shares and 1.31% stock option, employees. The remaining 89.49% were publicly traded.


Head office

In January 2012, Sanofi moved its head office location to 54, Rue La Boétie in the 8th arrondissement of Paris. This former mansion designed by architect René-Patouillard had previously been the head office of Alcatel-Lucent. Sanofi's previous head office was located in the 13th arrondissement of Paris, at 174 Avenue de France. The architecture of the head office is of the predominant style of the area surrounding the François Mitterrand Library. After Sanofi and Aventis merged, the employees at the former Aventis head office in Schiltigheim, Alsace, moved to Paris. In November 2022, Sanofi moved into its new global headquarters in the 17th arrondissement of Paris, at 46-48 Avenue de la Grande Armée.


Collaborative research

In addition to internal research and development activities, Sanofi is also involved in publicly funded collaborative research projects, with other industrial and academic partners. One example in the area of Pre-clinical development, non-clinical safety assessment is the Innovative Medicines Initiative, InnoMed PredTox project The company is expanding its activities in joint research projects within the framework of the Innovative Medicines Initiative of EFPIA and the European Commission. In June 2010, Sanofi and the Charité, Charité University of Berlin signed a cooperation agreement for the research and development of medicines and therapies. On 25 October 2012, Sanofi said its earnings for the third quarter slumped, as generic competitors ate into profits from its Eloxatin cancer treatment.


Sanofi Pasteur

In 2005, Sanofi Pasteur, the vaccines division of Sanofi Group, was awarded a $97 Million United States Department of Health and Human Services (HHS) contract.


BCG supply shortage 2012–2014

In 2011, a Sanofi Pasteur plant flooded, causing it problems with mold. The facility, located in Toronto, Ontario, Canada, produced BCG vaccine products, made with the Glaxo 1077 strain, such as a tuberculosis vaccine ImmuCYST, a BCG Immunotherapeutic, a bladder cancer drug. By April 2012, the FDA had found dozens of documented problems with sterility at the plant, including mold, nesting birds, and rusted electrical conduits. The plant was closed for over two years, resulting in shortages of bladder cancer and tuberculosis vaccines. On 29 October 2014 Health Canada gave Sanofi permission to resume production of BCG.


COVID-19 vaccine

In 2020, Sanofi, together with GSK, signed a deal with the US government's Operation Warp Speed to provide 100 million doses of COVID-19 vaccine for up to US$2.1 billion, if the vaccine was approved. As of August 2020, COVID-19 vaccine development in Sanofi underscored its fundamental competitiveness weakness, with which management has been struggling and failed to deal with for many years, beyond cutting more costs. Unfortunately, even though the approach of Sanofi-GSK is based on pre-existing, approved platforms and technology (as with Flublok flu), without reinventing the wheel of the necessary infrastructure, the company lagged behind many other rivals in delivering a working vaccine. Sanofi planned to start Phase 1 clinical testing only in September and expected emergency use approval in the first half of 2021. Competitors such as Novavax had already completed Phase 1 studies, with promising results, and Moderna-NIH had already initiated its Phase 3 trial. According to CNBC reports, as part of the $2.1 billion US government deal, more than 750 million went to supporting Sanofi-GSK in vaccine development and clinical trials. Sanofi turn-outs "accelerate" the development via a smaller biotech firm, Translate Bio, with a $425M partnership. At the end of September 2021, Sanofi announced that it would stop developing its mRNA COVID-19 vaccine. Despite promising results, the drug would not continue to Phase 3 trials, and the company stated that it would be 'too late to reach the market.'


Opella

Opella is the former Consumer Healthcare (CHC) division of Sanofi, established as an independent company headquartered in France on April 30, 2025. Its formation followed the sale of a 50.0% controlling stake by Sanofi to the private equity firm Clayton, Dubilier & Rice (CD&R). Sanofi retained a significant 48.2% minority shareholding, while the French public investment bank Bpifrance acquired a 1.8% stake. The transaction provided Sanofi with approximately €10 billion in net cash proceeds.


Associations

Sanofi is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA), the Biotechnology Industry Organization (BIO), and the Pharmaceutical Research and Manufacturers of America (PhRMA). Sanofi's vaccine subsidiary,
Sanofi Pasteur Sanofi Pasteur is the vaccines division of the French multinational pharmaceutical company Sanofi. Sanofi Pasteur is the largest company in the world devoted entirely to vaccines. It is one of four global producers of the yellow fever vaccin ...
, is a member of EuropaBio. In June 2021, Sanofi partnered with Capgemini, Orange S.A., Orange & Generali Italia, Generali to launch Future4care, an all-European start-up accelerator centered on digital health.


Aventis Foundation

The Aventis Foundation, a Germany, German charitable trust, was established in 1996, as the Hoechst Foundation, with an Financial endowment, endowment of €50 million. In 2000, the foundation was renamed the Aventis Foundation. The foundation promotes cultural and scientific projects, specifically focused on the Frankfurt Rhine-Main area.


See also

* ''Amgen Inc v. Sanofi'', a United States Supreme Court case on patent enablement * Sanofi Biogenius Canada


Notes


References


External links

* * {{Authority control, state=expanded Sanofi, Biotechnology companies of France CAC 40 Companies in the Euro Stoxx 50 Companies in the Dow Jones Global Titans 50 Companies listed on Euronext Paris French brands French companies established in 1973 Healthcare companies of France Health care companies established in 1973 Multinational companies headquartered in France Pharmaceutical companies established in 1973 Pharmaceutical companies of France